Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pepcid 252-day Waxman/Hatch extension created by court has no statutory basis -- GPIA appeal brief.

Executive Summary

PEPCID 252-DAY WAXMAN/HATCH EXTENSION UNDER COURT RULING CHALLENGED by the Generic Pharmaceutical Industry Association in a brief submitted in the appeal of the consolidated case of Merck, Schering-Plough, Bracco and Roche v. FDA and the Patent & Trademark Office. Merck's Pepcid (famotidine) patent is one of 12 specifically at issue in the case, which seeks to overturn the PTO/FDA position that sponsors cannot add existing Waxman/Hatch patent extensions to the new 20-year-from-filing terms created by the General Agreement on Tariffs & Trade. The plaintiffs won the first round in the case when the Alexandria, Va. federal court ordered FDA to publish expiration dates as submitted by NDA holders ("The Pink Sheet" Oct. 23, 1995, T&G-1).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel